Alnylam Reports Positive Outcome Of FDA Advisory Committee Meeting On Patisiran For The Treatment Of The Cardiomyopathy Of ATTR Amyloidosis; FDA Has Set An Action Date Of October 8, 2023
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals has reported a positive outcome from an FDA Advisory Committee meeting regarding Patisiran, a treatment for the cardiomyopathy of ATTR amyloidosis. The CRDAC voted 9:3 in favor of the benefits of Patisiran outweighing its risks. The FDA has set an action date of October 8, 2023, under the Prescription Drug User Fee Act.
September 13, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive outcome of the FDA Advisory Committee meeting for Alnylam's Patisiran could potentially boost the company's stock in the short term.
The positive outcome of the FDA Advisory Committee meeting indicates a favorable view of Alnylam's Patisiran. This could lead to increased investor confidence in the company, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100